{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:32:20Z","timestamp":1783567940897,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clim.2024.110304","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:42:58Z","timestamp":1719967378000},"page":"110304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["CLADIN- CLADribine and INnate immune response in multiple sclerosis \u2013 A phase IV prospective study"],"prefix":"10.1016","volume":"265","author":[{"given":"Mastura","family":"Monif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Muscat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet","family":"Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Voo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fazzolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki E.","family":"Maltby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Lan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Seery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2024.110304_bb0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110304_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1525-1381.1999.09115.x","article-title":"A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis","volume":"111","author":"Romine","year":"1999","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"10.1016\/j.clim.2024.110304_bb0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2024.110304_bb0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2024.110304_bb0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","article-title":"Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes","volume":"62","author":"Carson","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.clim.2024.110304_bb0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbrc.2007.03.176","article-title":"Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes","volume":"357","author":"Fyrberg","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2024.110304_bb0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1042\/bj3590537","article-title":"Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria","volume":"359","author":"Marzo","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.clim.2024.110304_bb0040","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/00498254.2013.791762","article-title":"Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human","volume":"43","author":"Scheible","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clim.2024.110304_bb0045","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.clim.2024.110304_bb0050","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2024.110304_bb0055","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI114865","article-title":"Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy","volume":"86","author":"Carrera","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2024.110304_bb0060","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","article-title":"Cladribine activity in adult Langerhans-cell Histiocytosis","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clim.2024.110304_bb0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-121-6-199409150-00006","article-title":"2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis","volume":"121","author":"Saven","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2024.110304_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102962","article-title":"The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis","volume":"52","author":"Voo","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2024.110304_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2024.110304_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2024.110304_bb0085","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1523\/JNEUROSCI.5512-08.2009","article-title":"The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore","volume":"29","author":"Monif","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2012.02.002","article-title":"Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis","volume":"245","author":"Caragnano","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2024.110304_bb0095","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1111\/bph.14470","article-title":"P2X7 as a scavenger receptor for innate phagocytosis in the brain","volume":"175","author":"Gu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.clim.2024.110304_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clim.2024.110304_bb0105","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0110","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1093\/hmg\/ddv278","article-title":"A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis","volume":"24","author":"Gu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.clim.2024.110304_bb0115","first-page":"C1189","article-title":"Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors","volume":"279","author":"Gu","year":"2000","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.clim.2024.110304_bb0120","doi-asserted-by":"crossref","first-page":"23147","DOI":"10.1074\/jbc.M109.072793","article-title":"Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms","volume":"285","author":"Ward","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2024.110304_bb0125","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","article-title":"Human monocyte subsets and phenotypes in major chronic inflammatory diseases","volume":"10","author":"Kapellos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2024.110304_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.clim.2024.110304_bb0140","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0002-9440(10)63017-9","article-title":"CCR1+\/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis","volume":"159","author":"Trebst","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clim.2024.110304_bb0145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnen\/nlab083","article-title":"Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination","volume":"80","author":"Prineas","year":"2021","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.clim.2024.110304_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann. Neurol."},{"issue":"563\u2013576","key":"10.1016\/j.clim.2024.110304_bb0155","first-page":"ix","article-title":"The pathologic substrate of magnetic resonance alterations in multiple sclerosis","volume":"18","author":"Lassmann","year":"2008","journal-title":"Neuroimaging Clin. N. Am."},{"key":"10.1016\/j.clim.2024.110304_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clim.2024.110304_bb0165","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of Chronic Active Multiple Sclerosis Lesions with Disability in Vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2024.110304_bb0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clim.2024.110304_bb0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s11481-012-9387-7","article-title":"Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia","volume":"7","author":"Singh","year":"2012","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.clim.2024.110304_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.678817","article-title":"Cladribine treatment for MS preserves the Differentiative capacity of subsequently generated monocytes, whereas its administration in vitro acutely influences monocyte differentiation but not microglial activation","volume":"13","author":"Medeiros-Furquim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nn.4475","article-title":"The role of peripheral immune cells in the CNS in steady state and disease","volume":"20","author":"Prinz","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0190","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1084\/jem.20132477","article-title":"Differential roles of microglia and monocytes in the inflamed central nervous system","volume":"211","author":"Yamasaki","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2024.110304_bb0195","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00109-018-1672-3","article-title":"Contributions of monocytes to nervous system disorders","volume":"96","author":"Garr\u00e9","year":"2018","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.clim.2024.110304_bb0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coi.2007.10.010","article-title":"Antigen presentation by monocytes and monocyte-derived cells","volume":"20","author":"Randolph","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0205","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/icb.2015.42","article-title":"Monocyte:T-cell interaction regulates human T-cell activation through a CD28\/CD46 crosstalk","volume":"93","author":"Charron","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.clim.2024.110304_bb0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0165-5728(99)00106-X","article-title":"Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines","volume":"99","author":"Huang","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2024.110304_bb0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00005-010-0084-z","article-title":"Immunomodulatory effects of IFN-beta and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis","volume":"58","author":"Bartosik-Psujek","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.clim.2024.110304_bb0220","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.4049\/jimmunol.177.6.4196","article-title":"Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response","volume":"177","author":"Karni","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0225","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nn.2887","article-title":"Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool","volume":"14","author":"Ajami","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0230","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.4049\/jimmunol.161.7.3767","article-title":"Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice","volume":"161","author":"Tran","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12026-012-8297-3","article-title":"The three human monocyte subsets: implications for health and disease","volume":"53","author":"Wong","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2024.110304_bb0240","first-page":"e16","article-title":"Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood, The J American Soc Hematol"},{"key":"10.1016\/j.clim.2024.110304_bb0245","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF","volume":"168","author":"Belge","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-3083.2011.02641.x","article-title":"Fluorospot analysis of TLR-activated monocytes reveals several distinct cytokine-secreting subpopulations","volume":"75","author":"Smedman","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0255","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.immuni.2010.08.012","article-title":"Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors","volume":"33","author":"Cros","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2024.110304_bb0260","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.20011608","article-title":"The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting","volume":"196","author":"Randolph","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2024.110304_bb0265","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imcb.1025","article-title":"Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis","volume":"96","author":"Gjelstrup","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.clim.2024.110304_bb0270","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1189\/jlb.0105040","article-title":"CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data","volume":"79","author":"Soares","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2024.110304_bb0275","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/art.10545","article-title":"CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis","volume":"46","author":"Kawanaka","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110304_bb0280","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/IAI.66.6.2782-2790.1998","article-title":"Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis","volume":"66","author":"Nockher","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.clim.2024.110304_bb0285","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/art.20219","article-title":"Expression of toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis","volume":"50","author":"Iwahashi","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110304_bb0290","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2249.2010.04177.x","article-title":"Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease","volume":"161","author":"Koch","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2024.110304_bb0295","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1398-9995.2004.00546.x","article-title":"Comparative immunophenotyping of monocytes from symptomatic and asymptomatic atopic individuals","volume":"59","author":"Von Bubnoff","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2024.110304_bb0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/imcb.12004","article-title":"Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?","volume":"96","author":"Ajami","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.clim.2024.110304_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107270","article-title":"Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro","volume":"91","author":"Mathiesen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2024.110304_bb0310","article-title":"Oral Cladribine impairs intermediate, but not conventional, monocyte transmigration in multiple sclerosis patients across a model blood-brain barrier","volume":"24","author":"Lin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2024.110304_bb0315","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-510X(01)00680-3","article-title":"IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease","volume":"195","author":"Scarpini","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2024.110304_bb0320","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1172\/JCI5150","article-title":"Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients","volume":"103","author":"S\u00f8rensen","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2024.110304_bb0325","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1034\/j.1600-0404.2001.104002088.x","article-title":"Differential release of \u03b2-chemokines in serum and CSF of patients with relapsing\u2013remitting multiple sclerosis","volume":"104","author":"Sindern","year":"2001","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clim.2024.110304_bb0330","doi-asserted-by":"crossref","first-page":"34342","DOI":"10.1074\/jbc.M109.042671","article-title":"CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization","volume":"284","author":"Roca","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2024.110304_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173460","article-title":"Functional expression of P2X1, P2X4 and P2X7 purinergic receptors in human monocyte-derived macrophages","volume":"888","author":"Vargas-Mart\u00ednez","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.clim.2024.110304_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.662935","article-title":"Role of P2X7 receptors in immune responses during neurodegeneration","volume":"15","author":"Oliveira-Giacomelli","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0345","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2014.08.002","article-title":"P2X7 receptor: an emerging target in central nervous system diseases","volume":"35","author":"Sperl\u00e1gh","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.clim.2024.110304_bb0350","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12974-016-0621-8","article-title":"Interleukin-1beta has trophic effects in microglia and its release is mediated by P2X7R pore","volume":"13","author":"Monif","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2024.110304_bb0355","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00429-012-0491-5","article-title":"Microglia-derived proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1beta induce Purkinje neuronal apoptosis via their receptors in hypoxic neonatal rat brain","volume":"219","author":"Kaur","year":"2014","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.clim.2024.110304_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbih.2020.100062","article-title":"P2x7 receptors control demyelination and inflammation in the cuprizone model","volume":"4","author":"Bernal-Chico","year":"2020","journal-title":"Brain, Behavior, & Immunity - Health"},{"key":"10.1016\/j.clim.2024.110304_bb0365","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clim.2024.110304_bb0370","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11302-018-9620-9","article-title":"Administration of an antagonist of P2X7 receptor to EAE rats prevents a decrease of expression of claudin-5 in cerebral capillaries","volume":"14","author":"Grygorowicz","year":"2018","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.clim.2024.110304_bb0375","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1093\/hmg\/ddv278","article-title":"A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis","volume":"24","author":"Gu","year":"2015","journal-title":"Hum. Mol. Genet."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624004133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624004133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:08:32Z","timestamp":1750147712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624004133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":75,"alternative-id":["S1521661624004133"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110304","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CLADIN- CLADribine and INnate immune response in multiple sclerosis \u2013 A phase IV prospective study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110304"}}